Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Illumina, San Diego, has expanded the reach of this NextSeq2000 Sequencing System with the commercial access to the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost 3 times greater than previously accessible on Illumina’s mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run on the system.
“The advanced yet affordable P3 flow cell for the NextSeq 2000 gives customers more capacity to increase the depth and breadth of their projects and the ability to stretch their project budgets, yielding deeper insights,” says Susan Tousi, chief product officer of Illumina. “We’re pleased to further instill customer confidence with the highest data quality ever achieved at commercial launch. Together with the on-instrument integration of our award-winning informatics solution and loss-less compression software, customers can extract actionable insights with a seamless user interface.”
“At University of Edinburgh, our genomics work includes single cell RNA sequencing projects which are often limited by cost,” says Lee Murphy, Head of the Genetics Core at the Edinburgh Clinical Research Facility. “With the NextSeq 2000 and P3 kits, we are experiencing higher output enabling more complex, informative studies which increases the value of our offerings to our world class researchers.”
“The NextSeq 2000 has enabled us to bring sequencing in-house that we would otherwise have to outsource,” says Bryan Venters, director of genomic technologies at EpiCypher, an epigenetic technology company located in North Carolina. “This is critical because it gives us control over our development pipeline. With the release of the P3 cartridge, it will enable higher throughput sequencing and faster turnaround times.”
The P3 flow cell is offered in four configurations, such as 100-, 200- and 300-cycles, providing 110 Gb, 220 Gb, and 330 Gb daily, respectively. In response to consumer feedback, Illumina is also starting a 50-cycle kit, targeting infectious disease, small RNA, and spatial transcriptomics applications. Furthermore, at the outset of 2021, the NextSeq1000 and NextSeq 2000 platforms may come with a tool designed to permit simple recycling of more than 60% of the reagent cartridge used in each sequencing run.
“Both the NextSeq 1000 and NextSeq 2000 are designed to simplify workflows and empower labs of any size with the economy of scale to sequence more, more frequently,” says Mark Van Oene, Chief Commercial Officer of Illumina. “With lower run costs, we’re empowering our customers to more freely pursue their research ideas and drive genomics forward.”
For more information, visit Illumina.
